When the complement cascade is strongly activated, the complement components C4b and C3b bind to mCRPs and inactivate them, but low levels of complement depositions are incapable of neutralizing sufficient percentages of the expressed mCRPs on the surface of the cancer cells. Here, C4B is linked to cancer.